In a research report issued today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Galena Biopharma (NASDAQ:GALE) with a $7 price target, as the …
In a research report issued Tuesday, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Galena Biopharma (NASDAQ:GALE) with an $8 price …
Galena Biopharma (GALE) announced today the resignation of CEO Mark Ahn and the instillation of COO, Mark Schwartz as its new CEO. In reaction …
In a research note issued earlier today, Roth Capital analyst Joseph Pantginis reiterated coverage with a “Buy” rating on Galena Biopharma, Inc. (GALE), and a …
